Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics

被引：2
|
作者：
Musil, Richard [1 ]
Spellmann, Ilja [2 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany
[2] Klinikum Stuttgart, Dept Special Psychiat Social Psychiat & Psychothe, Priessnitzweg 24, D-70374 Stuttgart, Germany
来源：
PHARMACOGENOMICS | 2018年 / 19卷 / 12期
关键词：
antipsychotics; cognitive symptoms; pharmacogenetics; schizophrenia; VAL(108/158) MET GENOTYPE; GENE-EXPRESSION; NEUROBIOLOGY; IMPAIRMENT; DOPAMINE; DEFICITS; PHASE-2; MATTER; DRUGS; TRIAL;
D O I：
10.2217/pgs-2018-0083
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Pharmacogenetic studies on cognitive effects of currently available antipsychotics, although in relatively early stages, suggest that the treatment of cognitive deficits in schizophrenia can be advanced toward a more precise future decision of antipsychotic treatment for individual needs.
引用
收藏
页码：927 / 930
页数：4
相关论文
共 50 条
  • [1] Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia
    Arranz, Maria J.
    Rivera, Margarita
    Munro, Janet C.
    [J]. CNS DRUGS, 2011, 25 (11) : 933 - 969
  • [2] Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia
    Maria J. Arranz
    Margarita Rivera
    Janet C. Munro
    [J]. CNS Drugs, 2011, 25 : 933 - 969
  • [3] PHARMACOGENETICS OF ANTIPSYCHOTICS IN NEVER TREATED PATIENTS
    Lencz, Todd
    Robinson, Delbert
    Zhang, Jianping
    Gallego, Juan
    Yu, Jin
    John, Majnu
    Kane, John
    Correll, Christoph
    Malhotra, Anil
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S355 - S355
  • [4] Pharmacogenetics of antipsychotics in schizophrenia
    Meary, Alexandre
    [J]. THERAPIE, 2008, 63 (03): : 243 - 246
  • [5] Prefrontal cognitive deficits in patients with schizophrenia treated with atypical or conventional antipsychotics
    Müller, U
    Werheid, K
    Hammerstein, E
    Jungmann, S
    Becker, T
    [J]. EUROPEAN PSYCHIATRY, 2005, 20 (01) : 70 - 73
  • [6] Basal cortisol concentrations and symptoms severity in patients with schizophrenia treated with atypical antipsychotics
    Wilczynski, K.
    Tobolska, D.
    Lorek, M.
    Mazgaj, E.
    Krysta, K.
    Krzystanek, M.
    Gawlik, A.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S422 - S423
  • [7] Cognitive Outcomes in Nonacute Patients With Schizophrenia Treated With Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics
    Petric, Paula Simina
    Teodorescu, Andreea
    Miron, Ana Aliana
    Manea, Mihnea Costin
    Ifteni, Petru
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (03) : e219 - e228
  • [8] DYSLIPIDEMIA IN PSYCHIATRIC PATIENTS WITH SCHIZOPHRENIA, TREATED WITH ANTIPSYCHOTICS
    Ladea, M.
    Exergian, A. M.
    Barbu, C. M.
    [J]. ACTA ENDOCRINOLOGICA-BUCHAREST, 2013, 9 (04) : 647 - 653
  • [9] SEXUAL DYSFUNCTION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS
    Mendonca, C.
    Bras, A.
    [J]. EUROPEAN PSYCHIATRY, 2013, 28
  • [10] IMPROVEMENT IN NEGATIVE SYMPTOMS IN PATIENTS TREATED WITH ANTIPSYCHOTICS
    Novick, Diego
    Montgomery, William
    Treuer, Tamas
    Bertsch, Jordan
    Haro, Josep Maria
    [J]. SCHIZOPHRENIA RESEARCH, 2014, 153 : S250 - S250
12345